decisionhealth Newsletters, Coder Pink Sheets - 2003 Issue 10 (October)
Visudyne discounts
Subscribe or sign in to view the full article.
Article Overview
This article addresses how discounts related to a high-cost ophthalmic drug are discussed in the context of billing, Medicare disclosure expectations, and anti-kickback safe harbor concerns. It is relevant to ophthalmology practices, billing staff, and compliance professionals who handle drug reimbursement, payer contract issues, and record retention. The article also includes broader Medicare participation-rate information by specialty and notes that state and private payer requirements may differ.
Why This Topic Matters
Practices that administer or bill for costly specialty drugs need to understand when discounts may be retained, what records should be maintained, and when disclosure obligations can vary by payer or state law. The article helps readers recognize that billing, contracting, and compliance processes may differ depending on whether the drug is supplied by the practice or another facility.
What You Will Learn
- How discount-related issues can arise in billing for a specialty ophthalmic drug
- What general compliance and recordkeeping topics are discussed in connection with discounts
- Why Medicare, state programs, and private payers may be treated differently
- How practice setting and drug supply arrangements can affect billing concerns
- What specialty participation-rate data are presented alongside the reimbursement discussion
Who Should Read This
- Ophthalmologists
- Retina specialists
- Optometrists
- Medical billing staff
- Practice managers
- Compliance officers
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com